⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 16, 2024ACS Infectious Diseases

Development and Evaluation of Bis-benzothiazoles as a New Class of Benzothiazoles Targeting DprE1 as Antitubercular Agents

Rabiya Samoon Shashikanta Sau Arnab Roy Kishan Kumar Parida Kalicharan Sharma Prasanna Anjaneyulu Yakkala Rikeshwer Prasad Dewangan Malik Zainul Abdin Nitin Pal Kalia Syed Shafi

View at Publisher

Ask AI

Bookmark

Share

Abstract

Benzothiazole-bearing compounds have emerged as potential noncovalent DprE1 (decaprenylphosphoryl-β-d-ribose-2'-epimerase) inhibitors active against

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Samoon et al. (2024) studied this question.

synapsesocial.com/papers/68e5be81b6db643587556a0b https://doi.org/10.1021/acsinfecdis.4c00415

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Small Peptide Conjugates of Benzothiazole‐2‐Carboxylic Acids Targeting DprE1 Against Tuberculosis2024 · 7 citations
2Novel hybrids of 1,2,3-triazole-benzoxazole: design, synthesis, and assessment of DprE1 enzyme inhibitors using fluorometric assay and computational analysis2024 · 12 citations
3Pyrazolopyridine pyrimidone hybrids as potential DprE1 inhibitors, design, synthesis and biological evaluation as antitubercular agents2025 · 13 citations
4Current perspectives on DprE1 inhibitors as antitubercular agentsHuman Clinical Trial · 2026
5Noncovalent inhibitors of DprE1 for tuberculosis treatment: design, synthesis, characterization, <i>in vitro</i> and <i>in silico</i> studies of 4-oxo-1,4-dihydroquinazolinylpyrazine-2-carboxamidesIn Vitro Study · 2024 · 1 citations